New COVID Variant BA.2.3.2 Detected in Children Globally

A newly tracked COVID-19 variant, BA.3.2, is drawing attention from scientists because it is being detected more often in children than other circulating variants. Researchers describe BA.3.2 as a branch of the Omicron family and say it has been identified in 23 countries. As of April 2, 2026, it has also appeared in wastewater samples from 25 U.S. states.

Scientists say BA.3.2 appears to be circulating at relatively low levels, but they caution that its true spread could be higher than reported. They attribute that uncertainty to reduced testing, which can limit how quickly and accurately variant patterns are captured. Monitoring through wastewater is being used as an additional signal of where the variant may be present.

BA.3.2 has a large number of genetic changes compared with earlier versions of the virus. Scientists report 53 changes to its spike protein relative to its parent BA.3, and about 70 mutations compared with the original 2019 coronavirus. Despite the scale of these changes, experts say there is no indication that BA.3.2 is causing more severe illness in children or adults.

Available vaccines are believed to provide some protection against BA.3.2, according to experts. They also do not recommend updating existing vaccines specifically for this variant, citing its limited impact so far. Scientists say the focus remains on tracking whether BA.3.2 develops characteristics that would raise its public health significance.

The variant was first identified in November 2024 from a 5-year-old in South Africa, scientists said. After a period of dormancy, it re-emerged, which contributed to its nickname, “Cicada.” Researchers say this pattern has reinforced the need for continued surveillance even when a lineage appears to fade.

Data from New York City suggests a notable difference in who is being infected. Scientists report that children are about five times more likely to be infected with BA.3.2 than with other variants. Experts say they are watching for any shift in transmission patterns or clinical outcomes that could change how health systems and policymakers respond.